" class="no-js "lang="en-US"> Amgen - Medtech Alert
Tuesday, June 06, 2023
Amgen | Pharmtech Focus


About Amgen


Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

See our Community Guidelines: bit.ly/smcgl

Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.

Related Story

Amgen to Acquire Chemocentryx for $4 Billion in Cash

August 5 2022

Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to […]

IDEAYA Announces Clinical Trial Collaboration With Amgen to Evaluate MAT2A-PRMT5 Synthetic Lethality Combination in MTAP Deleted Tumors

July 28 2022

IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company committed to the […]

Hundreds of Patients to Benefit From Revolutionary Lung Cancer Drug On The NHS

March 3 2022

A revolutionary targeted drug for lung cancer will be made available to anyone who is […]

Owkin and Amgen Use AI to Improve Cardiovascular Risk Prediction

December 17 2021

AI startup Owkin and Amgen have announced the results of a three-year project to use […]

Amgen Begins Construction On New Biomanufacturing Plant In Central Ohio

November 8 2021

Amgen (NASDAQ:AMGN) today announced the groundbreaking of its newest biomanufacturing plant, located in New Albany, Ohio. The […]

Amgen and Neumora Therapeutics Announce Strategic R&D Collaboration to Accelerate Novel Precision Therapies for Brain Diseases

October 7 2021

Amgen (NASDAQ: AMGN) and Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company pioneering precision medicines for […]

FDA Approves Repatha ® (evolocumab) in Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia

September 27 2021

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Repatha ® (evolocumab) as an […]

Amgen to Acquire Privately Held Teneobio for $900 Million in Cash With Future Contingent Milestone Payments

July 28 2021

Amgen (NASDAQ: AMGN) and Teneobio today announced an agreement under which Amgen will acquire Teneobio, a […]

Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis

June 1 2021

Amgen (NASDAQ: AMGN) and Kyowa Kirin Co., Ltd. (TSE: 4151) today announced an agreement to jointly develop and […]

Amgen Tezepelumab BLA Submitted to U.S. FDA

May 11 2021

Amgen (NASDAQ:AMGN) today announced its partner AstraZeneca (NASDAQ:AZN) submitted a Biologics License Application (BLA) to […]

FDA Accepts Amgen's sNDA For Otezla ®

May 6 2021

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for […]